Literature DB >> 7779250

Cytokine-binding proteins: stimulating antagonists.

B Klein1, H Brailly.   

Abstract

Cytokine-binding proteins (CBPs) block the ability of cytokines to interact with their receptors. These agents can potentially provide a means of treating pathological conditions that have a significant cytokine involvement. However, a major drawback of such approaches relates to the fact that CBPs stabilize the cytokine in the form of a cytokine-CBP complex in vivo. Here, Bernard Klein and Hervé Brailly discuss the possibility that CBPs behave either as agonists or antagonists according to their pharmacokinetic characteristics in vivo, and suggest a mechanism by which stable complexes might be cleared from the system.

Mesh:

Substances:

Year:  1995        PMID: 7779250     DOI: 10.1016/0167-5699(95)80161-8

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  19 in total

1.  Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Authors:  J-F Rossi; N Fegueux; Z Y Lu; E Legouffe; C Exbrayat; M-C Bozonnat; R Navarro; E Lopez; P Quittet; J-P Daures; V Rouillé; T Kanouni; J Widjenes; B Klein
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

2.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.

Authors:  Sven Létourneau; Ester M M van Leeuwen; Carsten Krieg; Chris Martin; Giuseppe Pantaleo; Jonathan Sprent; Charles D Surh; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

3.  A pharmacokinetic approach for evaluating cytokine binding macromolecules as antagonists.

Authors:  M Ramanathan
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

4.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

5.  Modulatory effect of antibiotics on cytokine production by human monocytes in vitro.

Authors:  K Morikawa; H Watabe; M Araake; S Morikawa
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 6.  Innate immunity and the failing heart: the cytokine hypothesis revisited.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

Review 7.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 8.  Virus-induced immunopathology.

Authors:  B T Rouse
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

9.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

Authors:  H C van Zaanen; R P Koopmans; L A Aarden; H J Rensink; J M Stouthard; S O Warnaar; H M Lokhorst; M H van Oers
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease.

Authors:  A Sergeeva; Y Ono; R Rios; J J Molldrem
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.